Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under
supportive conditions, is safe and effective for depression in people with Mild Cognitive
Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether
psilocybin may improve quality of life in those individuals.